Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
D. Tomaras
ResearcherPublications, citations & collaboration network
D. Tomaras is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 27 works, 66 citations, an h-index of 4 and an i10-index of 2.
27
Works
66
Citations
4
h-index
2
i10-index
IDs:OpenAlex
How has D. Tomaras's publication output changed over time?
ScholarIQpublication output · 2018–2022
Output grew0% over the shown period — from 1 works in 2018 to 1 in 2022.
1
2
4
2
1
20182019202020212022
What are the most-cited papers on D. Tomaras?
ScholarIQmost cited works
Non-small cell lung cancer with <i>EGFR</i> exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes
C.S. Kwon, Huamao Mark Lin, Victoria Crossland, Eric N. Churchill, Eileen Curran, Anna Forsythe, D. Tomaras, Sai‐Hong Ignatius Ou
Current Medical Research and Opinion. 202235 Citations
Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma
Jatin J. Shah, Sharon Shacham, Michael Kauffman, Patrick Daniele, D. Tomaras, Gabriel Tremblay, Olivier Casasnovas, Marie Maerevoet, Josée M. Zijlstra, George Follows, Joost S.P. Vermaat, Nagesh Kalakonda, André Goy, Sylvain Choquet, Éric Van Den Neste, Brian T. Hill, Catherine Thiéblemont, Federica Cavallo, Fátima De la Cruz, John Kuruvilla, Nada Hamad, Réda Bouabdallah, Ulrich Jäger, Paolo F. Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan‐Manuel Sancho, Michael Schuster, Miklós Egyed, Fritz Offner, T. Vasilakopoulos, Priyanka Samal, Ágnes Nagy, Matthew Ku, Miguel Canales
Future Oncology. 202111 CitationsOPEN ACCESS
1362P Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): A meta-analysis
D. Tomaras, Hongcao Lin, Anna Forsythe, Victoria Crossland, S-H.I. Ou
Annals of Oncology. 20206 Citations
Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
Gabriel Tremblay, D. Tomaras, E Strati, Anna Forsythe
Journal of health economics and outcomes research. 20214 CitationsOPEN ACCESS
Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis
Gabriel Tremblay, Qayyim Said, Beilei Cai, Shan Ashton Garib, D. Tomaras, Anna Forsythe, Anuja Roy
Blood. 20183 Citations
Related on ScholarIQ
Bristol-Myers Squibb (Canada)
Institution
Non-small cell lung cancer with <i>EGFR</i> exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes
Paper
Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma
Paper
1362P Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): A meta-analysis
Paper
Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
Paper
Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis
Paper